What Dose of Zepbound Is Most Effective for Weight Loss? The SURMOUNT-1 Data, Decoded

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• The 15 mg weekly dose produced the largest average weight loss in SURMOUNT-1: about 20.9 percent of body weight over 72 weeks. The 10 mg dose produced 19.5 percent. The 5 mg dose produced 15.0 percent.
• "Most effective" depends on what you're optimizing for. The 10 mg dose delivers about 93 percent of the weight loss of the 15 mg dose with somewhat lower side effects.
• Many patients reach their weight goal at 7.5 or 10 mg without ever needing to escalate to 15 mg. The label allows stopping the escalation at any tolerated dose that's working.
• A 5 percent weight loss by month 3 to 6 is the typical signal that any tirzepatide dose is working as expected.
• Genetics, baseline insulin resistance, diet, sleep, and exercise all modify response, which is why the SURMOUNT averages obscure significant individual variation.

Direct answer (40-60 words)

The 15 mg weekly dose of Zepbound produced the largest average weight loss in SURMOUNT-1 (about 20.9 percent of body weight over 72 weeks), but the 10 mg dose came close (19.5 percent) with somewhat better tolerability. For many patients, the most effective dose is the lowest one that drives consistent weight loss without intolerable side effects, often 7.5 or 10 mg.

Table of contents

1. The 30-second answer
2. The full SURMOUNT-1 dose-response data
3. Why "highest dose = best" isn't always true
4. The standard dose escalation schedule
5. When to stop escalating: signs your current dose is working
6. The 5 percent rule at month 3 and month 6
7. Why some patients don't need to reach 15 mg
8. Side effects across the dose ladder
9. Maintenance vs continued escalation
10. FAQ

The full SURMOUNT-1 dose-response data

SURMOUNT-1 (Jastreboff et al., NEJM 2022) is the phase 3 registration trial that earned Zepbound its FDA approval for weight management. The trial enrolled 2,539 adults with BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity (excluding type 2 diabetes). Participants were randomized to placebo, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly for 72 weeks alongside lifestyle counseling.

The primary endpoint was percent change in body weight at week 72.

A few observations from the data:

• The jump from placebo to 5 mg is much larger than the jump from 10 mg to 15 mg.
• About 84 percent of patients on 15 mg lost at least 10 percent of body weight, vs 78 percent on 10 mg. The marginal benefit of the higher dose is real but small.
• Roughly 57 percent of patients on 15 mg lost at least 20 percent of body weight. This is the "category-shifting" outcome that makes tirzepatide stand out from older anti-obesity medications.

In the SURMOUNT-3 extension (lifestyle intervention then tirzepatide), Wadden et al. (Nature Medicine 2023) showed that participants who continued on tirzepatide after a 12-week intensive lifestyle phase lost an additional 18.4 percent of body weight, on top of the 6.9 percent lost during lifestyle, for a total of about 24 percent.

Why "highest dose = best" isn't always true

The SURMOUNT-1 averages favor 15 mg as the most weight-loss-effective dose. But "most effective" is not always the same as "best for you." Several considerations:

Tolerability matters. Higher doses produce more nausea, vomiting, diarrhea, constipation, and reflux. In SURMOUNT-1, gastrointestinal adverse events at 15 mg were roughly 1.4 to 1.7 times the rate at 5 mg. Patients who experience severe GI side effects sometimes regress on weight loss because they eat erratically or stop the medication entirely.

The marginal benefit shrinks. The difference between 10 mg and 15 mg in SURMOUNT-1 was 1.4 percentage points of body weight on average. For a 200-pound starting weight, that's 2.8 pounds over 72 weeks of the higher-dose treatment. Whether 2.8 pounds justifies the extra side effect burden depends on the patient.

Some patients respond strongly at lower doses. A subset of patients in SURMOUNT-1 reached 15 percent or greater weight loss on 5 mg alone. For these patients, escalating to 10 or 15 mg adds side effects without much additional benefit.

Individual variation is large. The published averages obscure significant spread. Some 15 mg patients lost 35 percent of body weight; others lost 8 percent. Genetics, baseline metabolic state, diet, sleep, and physical activity all modify response.

The clinical principle most obesity-medicine specialists apply: escalate to the lowest dose that produces consistent, expected weight loss with manageable side effects. That dose may be 5, 7.5, 10, 12.5, or 15 mg depending on the individual.

The standard dose escalation schedule

The FDA-approved escalation schedule for Zepbound:

Each escalation step is a minimum of 4 weeks. Some prescribers extend to 6 to 8 weeks per step if side effects are bothersome or if the patient is losing weight at the current dose and doesn't yet need more.

The escalation is not mandatory. The label says "may be increased" rather than "must be increased." A patient who reaches 7.5 mg and is losing weight steadily and tolerating it well can stay there. A patient at 10 mg who has reached their goal weight can stay there indefinitely or transition to a lower maintenance dose.

When to stop escalating: signs your current dose is working

Your dose is working if, on average over 4 to 8 weeks at that dose, you observe:

• Steady weight loss of 0.5 to 1.5 percent of body weight per week (about 1 to 3 pounds per week for most patients early on, slowing as time goes on).
• Reduced appetite and reduced food intake consistent with the medication's mechanism.
• No worsening side effects beyond the typical first-week adjustment after each escalation.
• Sustainable weight trajectory rather than rapid loss followed by plateau.

You don't need to escalate if these markers are present. Escalating when the current dose is working can introduce side effects without proportionate benefit.

You should consider escalating if, after 6 to 8 weeks at your current dose, you observe:

• Plateaued weight (less than 0.5 percent change over 4+ weeks) while still above your goal.
• Returning appetite to pre-medication levels.
• Tolerable or no side effects at the current dose.
• Provider agreement that escalation is medically indicated.

The decision to escalate is a clinical judgment call, ideally made jointly with your prescriber based on actual data (weight, side effects, appetite ratings) rather than a fixed calendar schedule.

The 5 percent rule at month 3 and month 6

A useful rule from obesity medicine: if you haven't lost at least 5 percent of starting body weight by month 3 to 6 of treatment, your current regimen probably isn't working as expected.

Reasons a patient might miss the 5 percent benchmark:

• Dose too low. Still at 2.5 mg or 5 mg without escalation.
• Storage or technique issues. Compromised drug from storage above 46°F or freezing.
• Concurrent factors. New medications causing weight gain (steroids, certain antipsychotics), uncontrolled hypothyroidism, sleep apnea, etc.
• Caloric intake unchanged or increased. Some patients eat the same amount but feel less hungry; net energy balance is unchanged.
• Genetic non-response. A small percentage of patients (estimated 5 to 10 percent) don't respond to GLP-1 or GIP/GLP-1 agonists. Mechanism is incompletely understood.

If you're missing the 5 percent benchmark, the conversation with your provider should include: dose escalation if you're not already at maintenance, review of injection technique and storage, screening for confounding medications and conditions, and food log review for at least 7 to 14 days.

Why some patients don't need to reach 15 mg

In SURMOUNT-1, about 30 percent of patients on 5 mg lost more than 20 percent of body weight. That's the same outcome the trial averaged at 15 mg. These patients are sometimes called "high responders," and the predictors include:

• Lower baseline BMI. Patients starting at BMI 30 to 32 often respond more on percentage terms than patients starting at BMI 45+.
• Strong dietary adherence. Patients who use the medication-induced appetite reduction to consistently eat at a meaningful caloric deficit lose more.
• Active lifestyle. Patients who walk 8,000+ steps per day or do regular resistance training preserve more lean mass and lose more fat.
• Younger age. Younger patients (under 45) tend to respond somewhat more, possibly due to higher baseline metabolic rate.
• Female sex. SURMOUNT-1 showed a slight female advantage on percent weight loss, possibly related to body composition differences.

For high responders, escalating beyond 5 or 7.5 mg may add side effects without much benefit. Stopping escalation at the dose that's working is the standard recommendation.

Side effects across the dose ladder

The published SURMOUNT-1 data on dose-related adverse events:

A few patterns:

• Nausea is dose-dependent but plateaus between 10 and 15 mg.
• Vomiting is more dose-dependent and continues to increase across the ladder.
• Reflux climbs gradually across the doses (see our Zepbound and acid reflux article).
• Discontinuation due to side effects roughly doubles from placebo to 15 mg, but absolute rates are below 10 percent.

The takeaway: side effects are real and dose-related, but most patients tolerate the maintenance dose well after the initial 4 to 8 week titration.

Maintenance vs continued escalation

Once a patient reaches their weight-loss goal, two strategies exist for the long term:

Strategy 1: Stay at the dose that produced the weight loss. This is the SURMOUNT-1 trial protocol. Patients who lost weight on 15 mg continued on 15 mg through week 72. Continuing the same dose generally maintains the weight loss. Stopping or reducing the dose typically results in weight regain (Aronne et al., JAMA 2024 SURMOUNT-4 maintenance trial showed about 14 percent weight regain over 1 year after discontinuation).

Strategy 2: Reduce to a maintenance dose. Some patients who reach goal at 15 mg drop back to 10 or 7.5 mg for long-term maintenance. The clinical evidence for this approach is more limited but emerging. The principle: the dose needed to produce weight loss may exceed the dose needed to maintain it.

The decision between these strategies depends on side effect burden, cost, and individual response. Most prescribers will start with maintaining the trial dose and adjust downward if side effects warrant.

FAQ

What is the highest dose of Zepbound? The highest FDA-approved Zepbound dose is 15 mg once weekly. There is no approved 20 mg or higher dose. Patients should not exceed 15 mg without explicit provider direction.

What dose of Zepbound is most effective for weight loss? On average, 15 mg produced the largest weight loss in SURMOUNT-1 (about 20.9 percent over 72 weeks). The 10 mg dose was close (19.5 percent). For many patients, the most effective dose is the lowest one that drives consistent weight loss without unacceptable side effects, often 7.5 or 10 mg.

Is 15 mg of Zepbound twice as effective as 5 mg? No. In SURMOUNT-1, 5 mg produced 15.0 percent average weight loss; 15 mg produced 20.9 percent. The marginal increase from 5 mg to 15 mg is about 6 percentage points, not double. Most of the weight loss happens at the lower doses.

How long should I stay at each dose? The label specifies a minimum of 4 weeks per dose during titration. Many prescribers extend to 6 to 8 weeks per step if a patient is losing weight or if side effects are bothersome. There is no urgency to escalate.

Can I stay at 5 mg or 10 mg long term? Yes. The label allows maintenance at any tolerated dose that's working. If you're losing weight steadily at 5 or 10 mg without unacceptable side effects, there's no clinical mandate to escalate.

Do I need to reach 15 mg to lose meaningful weight? No. About 78 percent of patients on 10 mg lost at least 10 percent of body weight in SURMOUNT-1. Many patients reach their goal weight without ever escalating to 15 mg.

What if 15 mg isn't working for me? After 12 to 16 weeks at 15 mg, if weight loss has plateaued well above your goal, the conversation with your provider should cover dietary review, sleep, exercise, confounding medications, and possibly a switch to a different anti-obesity strategy. The label does not approve doses above 15 mg.

Is the dose for weight loss the same as for diabetes? The dose ladder is identical (2.5, 5, 7.5, 10, 12.5, 15 mg). The brand name differs: Zepbound for weight loss, Mounjaro for type 2 diabetes. Same molecule, same escalation, same maintenance options.

How much weight will I lose at 10 mg? SURMOUNT-1 averages: about 19.5 percent of body weight over 72 weeks. About 78 percent of patients on 10 mg lost at least 10 percent of body weight; about 50 percent lost at least 20 percent. Individual results vary widely.

Should I escalate if I'm losing weight steadily? Generally no. If your current dose is producing 0.5 to 1.5 percent body weight loss per week and side effects are tolerable, escalating adds side effects without much additional benefit until you plateau.

How do side effects compare across doses? Nausea, vomiting, and reflux are dose-related, but the curve is fairly flat between 10 and 15 mg. Constipation actually decreases slightly at 15 mg vs lower doses. Discontinuation rates due to side effects are 4.5 percent at 5 mg and 7.1 percent at 15 mg in SURMOUNT-1.

Is 12.5 mg useful? Yes, as a stepping-stone between 10 and 15 mg. Some patients tolerate 10 mg well but find 15 mg too rough. 12.5 mg can either be a final maintenance dose or a transition step.

Sources

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
2. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626.
3. Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3). Nature Medicine. 2023;29:2909-2918.
4. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA. 2024;331(1):38-48.
5. U.S. Food and Drug Administration. Zepbound (tirzepatide) Prescribing Information. Eli Lilly and Company, 2024.
6. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515.
7. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
8. Davies M, Faerch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week for adults with overweight or obesity and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984.
9. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-362 (with subsequent updates).
10. National Institute of Diabetes and Digestive and Kidney Diseases. Prescription Medications to Treat Overweight and Obesity. 2024.
11. Centers for Disease Control and Prevention. Defining Adult Overweight and Obesity. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.